GlassScriptPhysician profile
Chester L Strunk
NPI 1740281229
$8,137.59
in general payments reported to CMS, 2019-2025
28 companies · $2,536 in 2025
The $2,536 reported for 2025 was more than what 79% of Otology & Neurotology providers received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $333 · 2021: $398 · 2022: $1,609 · 2023: $2,261 · 2024: $879 · 2025: $2,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034 · Travel and Lodging: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.76 |
| Travel and Lodging | $1,641.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $3,111.10 | 2020-2025 | |
| Integra Lifesciences Corporation | $1,161.66 | 2024-2025 | Acclarent Aera, Inspira Air, Relieva Spinplus Nav |
| Genzyme Corporation | $874.76 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $545.45 | 2020-2025 | Dupixent |
| Optinose US, INC. | $459.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $416.56 | 2021-2025 | Nucala |
| Lilly USA, LLC | $207.30 | 2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $165.15 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $149.93 | 2025 | Tezspire |
| Alk-Abello, INC | $128.65 | 2020-2023 | Odactra, Grastek |
| Acclarent, INC | $110.28 | 2019-2023 | Trudi Nav Cable |
| Arbor Pharmaceuticals, INC. | $102.13 | 2019-2020 | |
| Itamar Medical INC | $101.60 | 2022-2025 | Watchpatone |
| Medtronic, INC. | $93.22 | 2023-2025 | Propel, Nuvent |
| Hikma Pharmaceuticals USA | $81.52 | 2024-2025 | Ryaltris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $77.19 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Intersect Ent, INC. | $72.87 | 2021 | |
| Xoran Technologies LLC | $71.50 | 2023 | Minicat |
| Ars Pharmaceuticals Operations, INC. | $39.54 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $23.30 | 2019 | |
| Olympus America INC. | $21.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.29 | 2021 | |
| Amgen INC. | $20.06 | 2025 | Tezspire |
| Eyevance Pharmaceuticals LLC | $19.58 | 2021 | |
| Merck Sharp & Dohme LLC | $18.37 | 2023 | |
| Medtronic USA, INC. | $18.23 | 2019 | |
| Phadia US INC. | $14.70 | 2025 | Immunocap |
| Stryker Corporation | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chester Strunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.